Journal of Oncology Pharmacy Practice

Article	Citations
Immunosuppressant adherence in adult outpatient hematopoietic cell transplant recipients	35
Mercaptopurine induced myelosuppression in a child with a NUDT15 rs116855232 homozygous variant	17
Nivolumab-induced immune-related neutropenia in a renal cell carcinoma patient	14
A room of errors simulation to improve pharmacy operators’ knowledge of cytotoxic drug production	14
Cellular therapy site-preparedness: Inpatient pharmacy implementation at a large academic medical center	14
Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer	14
Pharmacists’ practices and views regarding management of sexual health in patients with cancer	12
Hydroxyurea- a cost effective treatment in developing countries for Atypical Chronic Myeloid Leukemia (aCML): Case Report of Two Patients	12
Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities	12
Clinical characteristics and risk factors for oxaliplatin hypersensitivity reactions in patients with colorectal cancer	12
Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients	11
Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors	11
Comprehensive pharmacological geriatric assessment compared to usual care in an older adult with cancer in the absence of polypharmacy	11
Rituximab-induced severe acute thrombocytopenia in a patient with splenic marginal zone lymphoma	11
Corrigendum to A review on radiation induced nausea and vomiting: “Current management strategies and prominence of radio sensitizers”	11
Post COVID availability of oncology drugs – Is this the new normal on both sides of the Atlantic?	11
The physical exam’s role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma	11
Premedication strategy in cetuximab rechallenge after Grade 2 hypersensitivity reactions	10
Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 124 centers	10
Exploring the potential relationship between antineoplastic agents and their association with stomatitis and oral candidiasis in cancer patients	9
Trend analysis of pharmacist involvement in cancer care in Japan from 2015 to 2020: A nationwide survey study on hospital pharmacy practice	9
Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies	9
Assessing the impact of aprepitant on response to dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP)	9
Safety and efficacy of Vitamin C, Vitamin E, and selenium supplementation in the oncology setting: A systematic review	9
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer	9

Identifying health disparities in lenalidomide access	8
Evaluation of proteinuria monitoring practice patterns and treatment implications in patients with cancer receiving bevacizumab products	8
Acute pancreatitis associated with pembrolizumab-induced hypertriglyceridemia	8
Initial real-world experience with ribociclib in advanced breast cancer	8
Attitude of healthcare professionals toward the use of complementary and alternative medication during anti-cancer therapy	8
Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer	8
Cost-effectiveness of denosumab in preventing skeletal-related events in bone metastases	8
Evaluation of voriconazole related adverse events in pediatric patients with hematological malignancies	8
CAPhO Conference 2024 Abstract Book	8
Assessment of chemical contamination by cancer drugs during use of the RIVATM compounding robot: A pilot study	7
One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant	7
Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev®), a bevacizumab biosimilar, under extended in-use conditions	7
Management of chimeric antigen receptor T-cell induced cytokine release syndrome: Current and emerging approaches	7
Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions	7
Revitalizing oncology medications access in Saudi Arabia: Current challenges and recommendations by the Saudi Oncology Pharmacy Assembly	7
Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review	7
Efficacy and safety of bone management agents administered at 12 weeks vs. 4 weeks in patients with bone metastases: A systematic review	7
Melphalan on day -1 versus day -2 in patients with plasma cell disorders undergoing autologous stem cell transplant	7
Use of long-term corticosteroids in patients treated with CAR T-cell therapy	7
Prevalence and risk factors of trastuzumab induced cardiotoxicity in Tunisian HER2-positive breast cancer patients	7
Use of two general-purpose scales to assess clinical pharmacy activities in a cell transplantation unit	7
Gemcitabine-associated DRESS syndrome: A case report	7
Expanding oncology pharmacist teams: Justifying the return on investment	7
Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis	7
Nivolumab–ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment	7
Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective	7
Hypokalemia, hypomagnesemia, and hyponatremia are associated with acute kidney injury in patients treated with cisplatin	7
Evaluation of potential drug-drug interactions in cancer patients at a tertiary care hospital in Pakistan	6
Hepatic sinusoidal congestion associated with inotuzumab therapy in patients with B-cell acute lymphoblastic leukemia, a proposal for a new clinical entity: Calicheamicin syndrome	6
Safety and tolerability of adjuvant combination treatments following KEYNOTE-522 for early-stage or locally advanced breast cancer with residual disease	6
Evaluation of oral silymarin formulation efficacy in prevention of doxorubicin induced hepatotoxicity in patients with non-metastatic breast cancer	6
Innovation in hospital pharmacy: Modeling the installation of automated dispensing systems based on an oncology hospital experience transfer	6
Successful dasatinib therapy in newly diagnosed chronic myeloid leukemia in the setting of short bowel syndrome	6
Capecitabine-related neurotoxicity presenting with agraphia	6
QTc prolongation during levofloxacin and triazole combination chemoprophylaxis: Prevalence and predisposing risk factors in a cohort of hematopoietic cell transplantation recipients	6
Assessment of adverse events among cervical cancer patients at Kenyatta National Hospital	6
Papilledema and idiopathic intracranial hypertension due to the possible potentiation of ATRA by posaconazole in a case of acute promyelocytic leukemia	6
Pure red cell aplasia occurring during ibrutinib therapy for chronic lymphocytic leukemia	6
Pembrolizumab related perforated appendicitis	6
Rapid drug desensitization to taxanes: a descriptive study from Turkey	6
Vitreous hemorrhage: A rare ophthalmic adverse effect due to imatinib treatment	6
Preservation of cognitive function after brain irradiation	6
ISOPP Standards for the Safe Handling of Cytotoxics	6
Belantamab mafodotin for relapsed or refractory multiple myeloma	6
Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant	6
Intravenous route for folate supplementation in a patient with celiac disease treated by pemetrexed-based chemotherapy for non-small-cell lung cancer	6
Evaluating aggressiveness of end-of-life care in patients with advanced cancer: A retrospective single-center analysis	6
Pembrolizumab induced type 1 diabetes mellitus in a patient with metastatic melanoma and literature review on steroids as a treatment option	6
Perception, knowledge, and handling practice regarding the risk of exposure to antineoplastic drugs in oncology day hospitalization units and compounding unit staff	6
Retrospective cross-sectional study of drug utilisation and expenditure of anticancer drugs at zonal referral hospital central, Tanzania	6

Continuous versus intermittent tacrolimus for graft-versus-host disease prophylaxis in pediatric hematopoietic stem cell transplantation patients (Tic Tac)	6
Carfilzomib-induced thrombotic microangiopathy. A case report	6
Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma	6
The inpatient oncology pharmacist experience in the era of temporary oncologists	6
Medical marijuana in the treatment of cancer-associated symptoms	6
Inpatient utilization of immune checkpoint inhibitors and clinical outcomes	6
Oral oncolytic monitoring pilot with patient-reported outcomes and adherence assessments	5
Anti-cancer drug waste disposal practices and wastewater management in hospitals: A Lebanese survey	5
Evaluation of potential cost savings through chemotherapy and biotherapy dose-rounding at a pediatric institution	5
Investigating effective methods of clinical pharmacy training on oncology for community pharmacists: An observational study	5
Oral anticancer medicine interventions: A cross-sectional study in French community pharmacies	5
Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer	5
Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemothera	5
Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma	5
An assessment of the prevalence of drug therapy problems and its associated factors among ovarian cancer patients at Kenyatta National Hospital	5
Therapeutic outcomes of patients with acute erythroid leukemia treated with hypomethylating agents	5
Rasburicase induced methemoglobinemia: A systematic review of descriptive studies	5
Erratum to Evaluation of antibiotic appropriateness at an outpatient oncology centre	5
Chemotherapy-induced neutropenia among breast Cancer patients in a tertiary care hospital: Risk and consequences	5
Retrospective study on the efficacy and tolerability of dose modification of PD-1 and PD-L1 inhibitors in hospital-system community outpatient cancer clinics	5
Characteristics of the clinical pharmacist interventions at the National Center for Cancer Care and Research Hospital in Qatar	5
Perceptions and prevalence of marijuana use among cancer patients managed at an outpatient department in Zimbabwe: A brief report	5
Predictors of fluid overload in allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide	5
Immune checkpoint inhibition in advanced colorectal cancer with inherited and acquired microsatellite instability: Current state and future directions	5
Misalignment between patient preferences and clinician expectations: Do press releases make clinicians impatient to the detriment of patients?	5
Safety and oncological effectiveness after desensitization in patients with previous hypersensitivity reactions to chemotherapy	5
Comparison of first and third generation EGFR-TKIs for the treatment of advanced non-small cell lung cancer: A real-world study	5
Pharmacist's role in the management of drug–drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients	5
Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies	5
Acute infusion-related reactions in pediatric patients receiving etoposide at a tertiary cancer center	5
Dangerous interaction of bitter melon (Momordica charantia) with pazopanib: A case of acute pancreatitis	5
Not only a time-saving approach: Is it the time of subcutaneous formulation for daratumumab administration?	5
Genetic variants found in paediatric oncology patients with severe chemotherapy-induced toxicity: A case series	5
Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer	5
A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review	5
Adverse drug reactions associated with doxorubicin and epirubicin: A descriptive analysis from VigiBase	5
Descriptive analysis of the efficacity of R-GEMOX /R-IE/R-CEPP in patients with relapsed/refractory (R/R) transplant-ineligible diffuse large B-cell lymphoma (DLBCL)	5
Examining clinical pharmacist interventions and identifying opioid medication-related issues in patients with cancer	5
Evaluating patients on immune checkpoint inhibitors for cardiac adverse events: The EPICC study	5
Hypersensitivity reaction to Abiraterone, successful desensitization protocol in prostate cancer patient	5
The association between patient satisfaction with information and adherence to oral anticancer agents	4
Comment on ‘risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy’	4
Laryngopharyngeal dysesthesia as a possible clinical manifestation of a cytokine release reaction due to oxaliplatin	4
Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: An integrative review	4
Safe handling of hazardous drugs	4
Bilateral epithelial keratopathy and punctate keratitis due to ribociclib	4
Interstitial pneumonitis associated with leuprorelin acetate for a prostate cancer: A case report	4
A prospective analysis of efficacy of dexamethasone-sparing antiemetic regimens in high and moderate emetogenic chemotherapy	4
Effectiveness of antiemetic in reducing chemotherapy-induced nausea and vomiting in adult patients; An oncology center experience	4
Gefitinib induced Pemphigus Vulgaris with PRIDE complex	4
Myocarditis and diaphragmatic rhabdomyolysis with respiratory failure in a patient with metastatic melanoma treated with Nivolumab	4
Drug induced lupus associated with Trastuzumab emtansine in a patient with metastatic breast cancer	4
Automated chemotherapy compounding: Process optimization for the preparation of admixture containing high-dose of cyclophosphamide	4
Managing suspected myasthenia gravis and myositis induced by pembrolizumab in a Jehovah's Witness sarcoma patient	4
Cancer procoagulant inhibitors: New drugs for an old target	4
Poor tolerability of lenvatinib in elderly patients ≥80 years old with hepatocellular carcinoma: A multicenter observational study	4
Bevacizumab-induced isolated oculomotor nerve palsy in glioblastoma multiforme	4
Cytotoxic surface contamination in hospitals: Current practices, challenges and perspectives	4
Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R	4
Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 122 centers	4
Real-world experience of abemaciclib for adjuvant and metastatic breast cancer	4
Meperidine compared to morphine for rigors associated with monoclonal antibody-related infusion reactions	4
Drug-induced hypersensitivity syndrome following temozolimide for glioblastoma multiforme and the role of desensitization therapy	4
Residual contamination in antineoplastic drug packaging	4
A deep dive into CDK4/6 inhibitors: Evaluating real world toxicities and treatment paradigms in the elderly population	4
Skin toxicity after Filgrastim treatment for an Ewing's sarcoma patient	4
Acute pancreatitis secondary to tamoxifen-associated hypertriglyceridemia: A clinical update	4
Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: A randomized double-blind placebo controlled clinical trial	4
Panitumumab Associated Acute Pancreatitis	4
Cabozantinib-induced heart failure	4
Single center evaluation on the use of conditionally ordered low molecular weight heparins in malignant hematology patients with venous thromboembolism	4
Pembrolizumab for advanced non-small cell lung cancer (NSCLC): Impact of autoimmune comorbidity and outcomes following treatment completion	4
Carboplatin dosing in obese patients	4
Hand-foot syndrome and nail disorders secondary to treatment with paclitaxel: Is there a relationship with the presence of fungi?	4
Cost savings and cost avoidance with the inpatient clinical pharmacist interventions in a tertiary cancer care hospital	4
Rasburicase dose optimization for tumor lysis syndrome management in a network of community oncology practices	4
Imatinib mesylate-induced acute hepatotoxicity	4
Retrospective drug utilization review of meropenem and role of infectious disease pharmacist in specialized cancer care hospital	4
Acquired Hemophilia A following Pfizer-BioNTech SARS CoV-2 mRNA vaccine, successfully treated with prednisolone and rituximab	4
The role of the pharmacist in the hospital discharge of cancer patients: an integrative review	4

A case of palmar-plantar erythrodysesthesia in a lung cancer patient receiving atezolizumab maintenance	4
Reversible Cardiomyopathy after Rituximab Treatment in a Chronic Lymphocytic Leukemia Patient	4
Late side effects of cancer treatment in childhood cancer survivors	4
Medication errors in an oncology inpatient setting in India—Audit by clinical pharmacists	4
The effect of examining somatic alterations with NGS in patients with solid tumors, on patient management: A single-center experience in Turkey	3
Pro-BNP in the differential diagnosis of dyspnea in patients treated with immune-checkpoint inhibitors: Case Report	3
Drug extravasation with Enfortumab vedotin	3
Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome	3
Impact of telephone follow-up on hepatocellular carcinoma patients receiving oral chemotherapy from an ambulatory-care setting	3
Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better?	3
A study to quantify knowledge obtained during the British Oncology Pharmacy Association (BOPA) Introduction to Oncology (ITO) Course	3
Tamoxifen induced maculopathy presenting like macular telangiectasia type 2 in a patient with breast cancer	3
An assessment of exposed syringe inner walls as a route of exposure from hazardous drugs	3
Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma	3
Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation	3
Retrospective assessment of chemotherapy/biotherapy toxicity in a Hispanic/Latinx population versus published study population	3
Development of an African paediatric oncology pharmacy curriculum: A SIOP Africa 2024 pharmacy workshop output	3
Pharmacy practitioners’ adherence to safe-handling practices of chemotherapeutic drugs: A cross-sectional study in Saudi Arabia	3
A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions	3
Optimizing antimicrobial prophylaxis strategies in acute leukemia patients: Assessing the efficacy of fluconazole	3
Hypersensitivity reactions to chemotherapy and biologics: Outcomes and safety of 927 desensitization in Mexico	3
Defining cytotoxic drugs – you know it when you see it?	3
Optimizing intermittent dosing of oral small molecule inhibitors	3
New-onset persistent hyperglycemia with initiation of brentuximab treatment	3
Factors associated with potentially inappropriate medications in elderly with multiple myeloma	3
Artificial intelligence-based muscle analysis risk assessment of treatment-related toxicity in metastatic colorectal cancer	3
Development and use of an innovative Gap Finding Tool to create a Pharmaceutical Care Model within a paediatric oncology setting	3
Severe Generalized Weakness, Paraplegia following administration of Oxaliplatin in a patient with refractory T-cell non-Hodgkin lymphoma: A case report	3
Factors affecting medication adherence in patients using oral chemotherapy: A descriptive study	3
Patterns and predictors of antidepressant prescribing among adults with cancer and depression in ambulatory care settings in the United States	3
The relationship between immune-related adverse events during ipilimumab monotherapy and survival outcomes among melanoma patients: A systematic review	3
Life-threatening sustained hypocalcemia following Denosumab use in metastatic prostate cancer	3
Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK + ) advanced non-small cell lung cancer (NSCLC) with brain metastases	3
Vinorelbine-related tetraplegia due to severe peripheral neuropathy	3
Oncology stewardship practice in the United States: A Hematology/Oncology Pharmacy Association national survey	3
Redispensing of expensive oral anticancer medicines: A practical application	3
Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin's lymphoma	3
Cycle-dependent eosinophilia due to adjuvant nivolumab for malignant melanoma	3
Mild forms of thrombotic microangiopathy in patients with advanced pancreatic cancer receiving gemcitabine and nab-paclitaxel	3
Nephrotic syndrome induced by cetuximab in a patient with metastatic colorectal cancer	3
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia	3
Evaluating the clinical benefit of pembrolizumab as a first-line agent in advanced solid tumors: A comprehensive review	3
Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma	3
Assessment of potential drug–drug interactions in hospitalized cancer patients	3
Impact of obesity on doxorubicin pharmacokinetics in women with breast cancer	3
Midostaurin-Associated acute pancreatitis	3
Cytomegalovirus viremia and hepatitis B reactivation in patient with RET fusion-positive non-small cell lung cancer treated with pralsetinib	3
Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma	3
Central line-associated Rhizobium radiobacter bloodstream infection in two allogeneic hematopoietic cell transplant recipients	3
Rechallenges without desensitization following platinum-based chemotherapy reactions	3
Implementation of Partnered Pharmacist Medication Charting in haematology and oncology inpatients	3
Assessment of adverse drug reactions among acute myeloid leukaemia patients at Kenyatta National Hospital	3
Investigation of the frequency of bortezomib neuropathy in patients with multiple myeloma diagnosis with normal and abnormal genetic characteristics	3
A critical appraisal of South African oncology pharmacy standards: A comparison with international best practice standards	3
Successful Treatment of a 92-Year-Old Classic Kaposi's Sarcoma Man With Ultra-Low Dose Oral Etoposide	3
Evaluating the impact of a pharmacist-led venetoclax ramp-up clinic for chronic lymphocytic leukemia patients: A retrospective chart review	3
Hypercalcemia associated with interaction between all trans retinoic acid and fluconazole in an acute promyelocytic leukemia and acquired hypoparathyroidism case	3
Interpersonal communication-, education- and counselling-based interventions to support adherence to oral anticancer therapy: a systematic review	3
Advancements in the use of nanopharmaceuticals for cancer treatment	3
Implementation of pharmaceutical care service to elderly cancer patients in a tertiary care hospital in South India	3
Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma	3
Chronic cannabis use in breast cancer survivors: A questionnaire study of Israeli patients	3
Impact of low- and high-risk operators handling irinotecan on the blood contamination of health care workers in oncology day care units	3
Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring	3
Evaluating the efficacy of a premedication regimen including high-dose cetirizine in reduction of hypersensitivity reactions to paclitaxel: A retrospective cohort study	3
Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab	3
Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review	3
Enhancing access to expensive oncology medications in Pakistan: The critical role of pharmaceutical patient assistance programs in oncology care	3
A pilot study to determine the feasibility and safety of pharmacist and nurse driven management of venetoclax ramp-up in patients with chronic lymphocytic leukemia	3
Oncology pharmacy staffing survey across practice settings in the United States	3
The effect of Bevacizumab treatment on the incidence of hypertension in patients with ovarian cancer: a systematic review and meta-analysis	3
Role of Ketamine and Opioid Rotation in the Management of Opioid Induced Hyperalgesia in a Patient With Acute Promyelocytic Leukemia	3
Implementation of a pharmacist-guided pharmacogenomics dosing service at a rural NCI-designated comprehensive cancer center	3
Pharmacist interventions in optimising opioid medication therapy in pain management for palliative care patients: A systematic review	3
Herpesviral encephalitis associated with bortezomib use in a patient with multiple myeloma and associated light-chain amyloidosis	3
Effects of scalp lotion containing alpha lipoic acid derivatives for chemotherapy-induced alopecia in patients with gastrointestinal cancer: A prospective cohort study	3
Subacute cutaneous lupus erythematosus following ribociclib therapy for metastatic breast cancer	3
Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab	3
Role of clinical pharmacist in the palliative care of adults and elderly patients with cancer: A scoping review	3
Knowledge, attitudes, and practices among oncology pharmacists on cytotoxic drug reconstitution in Sri Lanka: A cross-sectional study	3
Antithrombotic and hemostatic stewardship: Evaluation of romiplostim for treatment of thrombocytopenia at a large academic medical center	3
Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia	3
A comprehensive study of adverse effects of chemotherapy on female breast cancer patients in NORI Cancer Hospital, Islamabad in a developing country	3
Evaluation of awareness about importance of high fever in leukemia and lymphoma patients receiving chemotherapy among healthcare professionals working in pharmacies other than hospital pharmacies: A s	3
Safety outcomes of teclistamab accelerated dose escalation	3
Preparations of exploration of immediate hypersensitivity to antineoplastic agents: An oncology pharmacy perspective	3
Incidence of invasive fungal infections in patients with chronic lymphocytic leukemia receiving ibrutinib within the veteran’s healthcare administration	3
Risk assessment of personnel exposure in a central cytotoxic preparation unit using the FMECA method	3
Phosphatidylinositol 3-kinase signaling inhibitors for treatment of multiple myeloma: From small molecules to microRNAs	3
Clinical pharmaceutical screening in critical situations in a radioiodine therapy management service	3
Manual versus automated chemotherapy preparation: A retrospective pharmaco-economic analysis	3
Pro-adherence complementary audiovisual educational intervention model for chronic myeloid leukemia patients treated with imatinib mesylate	3
Workflow evaluation of environmental contamination with hazardous drugs during compounding and administration in an UK hospital	3
Improving palbociclib adherence among women with metastatic breast cancer using a CONnected CUstomized Treatment Platform: A pilot study	3
Effects of piperacillin/tazobactam or cefepime on folinate dose in patients receiving high-dose methotrexate: A retrospective cohort study using Japanese administrative claims data	3